STOCK TITAN
  1. Home
  2. News
  3. EXAS

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.

In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.

The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.

  • Headquartered in Madison, Wisconsin
  • Specializes in cancer screening and diagnostic tests
  • Flagship product: Cologuard, a noninvasive colorectal cancer screening test
  • Precision oncology products: Oncotype DX and OncoExTra
  • Active development of liquid biopsy tests
  • Exclusive intellectual property rights protecting screening technology

For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.

News

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Rhea-AI Summary
Exact Sciences Corp. announces the online publication of the BLUE-C study results in The New England Journal of Medicine, showcasing the performance of their next-generation multitarget stool DNA test, Cologuard Plus, for colorectal cancer screening. The study demonstrated 94% sensitivity for CRC at 91% specificity, outperforming the fecal immunochemical test. Cologuard Plus aims to reduce unnecessary follow-up colonoscopies and is set to be available in 2025 pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
-
News

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

Rhea-AI Summary
Exact Sciences Corp. collaborates with The Blue Hat Foundation to launch 'Box Out Colon Cancer' campaign with Jamal Mashburn, promoting colorectal cancer screening and prevention during Colorectal Cancer Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.22%
Tags
none
-
News

Exact Sciences to Participate in March Investor Conference

Rhea-AI Summary
Exact Sciences Corp. (EXAS) to participate in TD Cowen 44th Annual Health Care Conference with a fireside chat on March 4, 2024. Investors invited to join via webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
News

Exact Sciences Announces Fourth Quarter 2023 Results

Rhea-AI Summary
Exact Sciences Corp. reports record revenue, positive free cash flow, and expects 2024 revenue of $2.810-2.850 billion. The fourth quarter and 2023 highlights include total revenue of $647 million, a 17% increase, with Screening revenue at $487 million and Precision Oncology revenue at $160 million. The company's financial results showcase growth in both revenue and cash flow, reflecting a strong performance in cancer screening and diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
earnings
-
News

Exact Sciences Schedules Fourth Quarter 2023 Earnings Call

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) plans to release its fourth quarter 2023 financial results on February 21, 2024, followed by a webcast and conference call to discuss financial results and business progress. The webcast and call will be open to all interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
earnings
-
News

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, and submits next-generation Cologuard to FDA. The company also announces Chief Financial Officer succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
earnings
News

Exact Sciences to participate in J.P. Morgan Healthcare Conference

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
-
News

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

Rhea-AI Summary
Exact Sciences (EXAS) awarded $1.3 million to 23 organizations through its FOCUS Program to improve colorectal cancer screening rates. Since 2022, the program has awarded $2.9 million to 50 organizations. The company developed Cologuard, the first FDA-approved noninvasive screening test, and has delivered over 13 million results since 2014.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Rhea-AI Summary
Exact Sciences Corp. (NASDAQ: EXAS) will present new data and study results at the 2023 annual San Antonio Breast Cancer Symposium (SABCS). The data includes updated TAILORx follow-up data, concordance analysis supporting the generation of Oncotype DX results from core needle biopsy, ADAPTcycle trial data, and prospective trial data regarding the potential omission of radiation therapy after surgery in certain patients with ductal carcinoma in situ (DCIS). The company aims to refine distant recurrence risk estimates, personalize treatment decisions, and expand the number of breast cancer patients able to forgo chemotherapy post-surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
News

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware, seeking damages and a court order to stop Geneoscopy from infringing on Exact Sciences' U.S. Patent No. 11,634,781. The patent covers methods for processing fecal samples at home for subsequent analysis in a clinical laboratory, central to Exact Sciences' Cologuard® stool DNA-based colorectal cancer screening test. After a reexamination by the USPTO, Geneoscopy's challenge to the patent was rejected, confirming its patentability for Exact Sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
none

FAQ

What is the current stock price of Exact Sciences (EXAS)?

The current stock price of Exact Sciences (EXAS) is $59.4 as of December 20, 2024.

What is the market cap of Exact Sciences (EXAS)?

The market cap of Exact Sciences (EXAS) is approximately 10.5B.

What is Exact Sciences Corp's main business?

Exact Sciences Corp specializes in molecular diagnostics, focusing on innovative cancer screening and diagnostic test products.

What is Cologuard?

Cologuard is a noninvasive stool-based DNA test designed to screen for colorectal cancer, integrated into major colorectal cancer screening guidelines.

Where is Exact Sciences Corp headquartered?

The company is headquartered in Madison, Wisconsin.

What are Oncotype DX and OncoExTra?

Oncotype DX is a suite of tissue-based genomic tests for cancer recurrence risk and chemotherapy benefit; OncoExTra is a liquid biopsy for comprehensive genomic profiling.

Is Exact Sciences developing any new tests?

Yes, the company is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

What is the significance of Exact Sciences' intellectual property?

Exact Sciences has exclusive intellectual property rights protecting its noninvasive molecular screening technology, reinforcing its market leadership.

Are Exact Sciences' products used internationally?

Yes, Exact Sciences provides cancer screening and diagnostic test products both in the United States and internationally.

How does Cologuard work?

Cologuard works by analyzing stool samples for DNA markers and blood that could indicate the presence of colorectal cancer or precancerous lesions.

What is the purpose of Oncotype DX tests?

Oncotype DX tests aim to estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy in breast and colon cancer patients.

Where can more information about Cologuard be found?

More information about Cologuard can be found at cologuardtest.com.

Stock EXAS logo
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

#828 Ranked by Market Cap
N/A Ranked by Dividends

EXAS Stock Data

10.55B
182.40M
1.01%
101.74%
7.48%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MADISON